Efficacy and safety of topical eprinomectin to control Myocoptes musculinus infestation in mice

Myocoptes musculinus is the most common fur mite identified among laboratory mice; infested mice, in addition to dermatological signs, may also be prone to secondary infections, affecting the outcome of a research trial. This trial was conducted in order to assess the safety and efficacy of a single topical administration of eprinomectin (5mg/kg BW) in a naturally infested laboratory mice colony. A safety trial was conducted on 20 uninfested pregnant females assigned to two groups, receiving eprinomectin and mineral oil, respectively. The mice were examined daily for signs of illness or toxicity; nests were individually weighted at 21 and 28 days postpartum. No acute toxicity was observed, all treated females gave full term delivery and number and mean weight of newborns ranged in the physiological values. To evaluate the efficacy, 20 naturally infested non-pregnant females were divided into two groups, treated as in the safety trial. Animals were observed daily for 15 min until 21 days post-treatment (DPT) and a “pruritus index” (PI: scratching and gnawing acts/mouse/min) was calculated. Pelage examination was performed on DPT 7, 14, 21 and 50. The “PI” was significantly lower in the treated group and mites were eradicated from all infested animals. A single topical administration of eprinomectin at a (high) dosage of 5mg/kg BW was safe and effective to control M. musculinus in mice.

Myocoptes musculinus is the most common fur mite identified among laboratory mice (FOX et al., 2002) and it has been associated with excessive pruritus; alopecia and a range of conditions, including ulcerative dermatitis, hypersensitivity dermatitis, and pyoderma can also develop (FOX et al., 2002(FOX et al., , 2007)).Infested mice may also be prone to secondary infections, reduced life span, and decrease of body weight (WELTER et al., 2007).
Here we reported the effectiveness and safety of a single topical administration of eprinomectin to control Myocoptes musculinus infestation in a naturally infested laboratory mice colony.
In January 2012, mice exhibiting excessive pruritus as the only clinical sign were signaled at a laboratory animal facility of the University of Turin, Italy.
The animal facility, including the environmental conditions (12-h light: 12-h dark cycle, RT 21 °C ± 1 °C and RH 55% ±5%) and animal housing were within the requirements established by European and National laws (86/609/CEE and DL 116/92).Animals housed in same-sex groups of 10 in transparent conventional polycarbonate cages (Tecnoplast, Buggirate, Italy) with isolator tops and corncob bedding, were fed rodent chow (4RF18GLP Rodent Diet, Mucedola Srl, Settimo Milanese, Italy) and provided with tap water ad libitum.Fur samples were obtained from 50 symptomatic animals, randomly selected in 50 different cages.
For pelage test, a 2×8 cm of clear scotch tape (Scotch® Crystal, 3M tm , Milan, Italy ) was thoroughly rubbed on the head, neck, back, ventral region of the thorax and abdomen of each mouse.The tape was then affixed to a glass microscope slide with a drop of oil and examined for ectoparasites at 40x magnification.
A pelage sample was also cultured on Mycobios-selective agar (Biolife Italiana Srl, Milan, Italy) to exclude concomitant dermatophytosis as the cause of the dermatological lesions.
Pelage examination revealed Myocoptes musculinus adult fur mites and/or larvae and/or eggs in all the 50 mice examined.No other ectoparasites were detected, and all cultures were negative for dermatophytes.
Since the lifecycle of M. musculinus ranges from 8 to 14 days, with eggs hatching in 5 days (FOX et al., 2002), and because of its surface-feeding nature, in the effort to develop a simple and rapid one-time treatment protocol, a single topical administration of eprinomectin was tested.
A preliminary safety trial was conducted on 20 FVB/NCrl uninfested pregnant females (term delivery at 24 h-10 days); animals were isolated in individual cages and randomly assigned to one of two experimental groups of 10.Group A received pour-on eprinomectin (Eprinex® Pour-on, Merial Italia SpA, containing 0.5% active ingredient) at the approximate dosage of 5 mg/kg BW (27µL/mouse).Eprinex® Pour-on was topically applied to the skin in a single spot at the base of the neck.Control mice (Group B) received 27µL mineral oil on the same day.Mice were examined daily for any signs of illness or toxicity, including neurological abnormalities; moreover, to monitor the growth, nests were individually weighted at 21 and 28 days post partum.
No acute toxicity was observed in 10 treated mothers, and gross behavior and appetite were not affected.All treated females gave full term delivery and number of newborns ranged from 4 to 7, for a total of 58 mice.The mean weight of newborns was 10.8+0.3 g at the age of 3 weeks, and 16.1+0.4g at the age of 4 weeks, ranging in the physiological values of the corresponding line (Charles River Laboratories, 2004).No statistical differences were recorded in controlled mice, regarding the number of newborns (a total of 60, ranging from 4 to 8) and the mean weight 11.5 grams+0.5 g at the age of 3 weeks and 16.8 grams+0.3g at 4 weeks.
In parallel, an efficacy trial was carried out on 20 naturally infested non-pregnant females, which were divided into Groups C and D, based on detection of fur mites and/or their eggs.A third group (Group E) of 10 uninfested mice served as untreated control.On Day 0, Group C received pour-on eprinomectin (same formulation, application and dosage as in the safety trial); positive control mice (Group D) and uninfested mice (Group E) received 27µL mineral oil on the same day.Each group was observed daily for 15 min, during the 3 days of pre-treatment up to 21 days post-treatment; observation involved evaluation of clinical signs of infestation such as scratching, alopecia, rough coat, presence of scabs or sores, and trauma to ears or skin or no outward clinical signs of infestation.
All scratching and gnawing acts were recorded and a "pruritus index" (acts/mouse/min) was calculated, according to Jensen et al. (2002) and Loewenstein et al. (2006).The presence/absence of mites and/or their eggs was estimated in all mice within Groups C and D by double (ventral and dorsal) pelage tape test on experimental days 7, 14, 21 and 50.Numbers of scratching and gnawing acts recorded in Groups C and D were compared by the Student's t-test.
No side effects or signs of illness were observed in any of the treated animals.Treatment resulted in clinical improvement after the first week following Eprinex® Pour-on administration.After the first day of post-treatment a significant decrease (P≤0.001) of scratching and gnawing acts was recorded (Figure 1).On day 7 pelage tape tests showed that all mites were eliminated; only empty and unviable desiccated eggs (Figure 2) were observed in the treated group on days 7, 14 and 21 (in 70%, 90% and 20% of mice, respectively), and no egg or mite on day 50.
Positive control mice showed no clinical improvement compared to the treated group, the "pruritus index" was significantly (from P≤0.01 to ≤0.001) higher in all three experimental weeks.
At the end of the trial positive control mice were treated.Fur mites infestations in research colonies remain a constant management challenge.Fur mites have been reported to interfere with established research models by directly potentiating allergictype hypersensitivity reactions (MORITA et al., 1999), indirectly interfering with normal immune responses to other (WELTER et al., 2007) and have been shown to provoke a Th2 immune response and elevate serum IgE (LALTOO et al., 1979;JUNGMANN et al., 1996).
In spite of the labor and time saving of oral administration in drinking water or food, a widespread acaricide treatment could be contraindicated due to the potential for adverse effects; for example, ivermectin and moxidectin, although effective against fur mites, can be lethal in neonatal pups and genetically modified mice with defective blood-brain barriers (SCHINKEL et al., 1994;SKOPETS et al., 1996); moreover, moxidectin was also associated to an episode of acute toxicosis and mortality after routine prophylactic treatment in two strains of mice (LEE et al., 2009).
Topical administration, even if it requires a more intensive labor, ensures accurate dosing of the single mouse and prevents inadvertent toxicosis.
Under the conditions of this study, the tested single-dosage had similar efficacy as the single-dosage topical treatment with moxidectin, which is a well recognized operator-friendly option for control and eradication of the fur mite in large colonies of laboratory mice.
A single topical administration of eprinomectin at a high dosage of 5 mg/kg BW was safe and effective in the control of M. musculinus in mice.

Figure 1 .
Figure 1."Pruritus Index" (acts/animal/min) recorded for each experimental group (dotted line: control health group; blue line: infested treated group; red line: infested untreated control group).